Patients with tumors larger than 5 cm, TNM stages III–IV, and microvascular invasion exhibited higher IL-26 expression, underscoring the prognostic significance of this cytokine in predicting adverse outcomes in HCC patients [73]. This evidence concerns the gene IL26 and hepatocellular carcinoma.